AHA: AstraZeneca's Brilinta linked to less bleeding solo than as an aspirin add-on

AstraZeneca's longtime clot-buster Brilinta has seen some of its shine wear off as other drugs—not the least of which SGLT2 star Farxiga—have charted a new course. But the British drugmaker still has hopes for its old stalwart, and aspirin-beating bleeding data in acute coronary syndrome could help.